MOTS-c injection is a research peptide studied for metabolic and exercise-mimicking effects. Learn how it's used, typical research dosages, and safety facts.
MOTS-c injection is the administration of a mitochondrial-derived peptide called MOTS-c through a syringe, most often subcutaneously in laboratory research. It is not FDA-approved for human use, and no human clinical dosage has been established. Scientists study MOTS-c injections for their effects on metabolism, insulin sensitivity, and exercise capacity in animal models.
What Is MOTS-c and Why Is It Injected?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Its name stands for mitochondrial open reading frame of the 12S rRNA-c. It was identified in 2015 and is sometimes described as an exercise mimetic because it activates AMPK and influences glucose metabolism. The peptide is not naturally stable when taken orally, so researchers use injection to deliver it directly into the bloodstream or tissue.
A MOTS-c peptide injection is typically prepared by dissolving lyophilized powder in a sterile diluent. In rodent studies, common routes include subcutaneous and intraperitoneal injection. Human data on injection routes, absorption, and clearance do not exist.
How Researchers Prepare and Administer MOTS-c
Laboratory protocols usually call for reconstituting the peptide with bacteriostatic water for injection, which contains 0.9% benzyl alcohol to inhibit bacterial growth. Suppliers often list 30ml bacteriostatic water for injection as a standard size for research use. Sterile technique matters because contaminated injections can cause infection or inflammation.
Once reconstituted, the solution is stored refrigerated and protected from light. Researchers typically use it within a few weeks. Freezing reconstituted peptide can degrade it, so most protocols recommend against it.
Proposed Research Benefits of MOTS-c
Animal studies suggest MOTS-c may improve insulin sensitivity, reduce diet-induced obesity, and increase physical endurance. Some research links declining MOTS-c levels to age-related metabolic dysfunction. These findings are preliminary and have not been confirmed in controlled human trials.
- Improved glucose uptake in skeletal muscle
- Reduced fat accumulation in mice fed a high-fat diet
- Increased AMPK activation, a cellular energy sensor
- Possible protection against age-related metabolic decline
MOTS-c Injection Dosage in Studies
Dosing information comes almost entirely from animal research. Human equivalent doses are speculative and should not be used for self-administration. The table below summarizes common research protocols.
| Study Model | Typical Dose | Route | Frequency |
|---|---|---|---|
| Mice (metabolic studies) | 0.5 mg/kg | Intraperitoneal | Daily for 1–4 weeks |
| Mice (exercise studies) | 0.5 mg/kg | Subcutaneous | Daily or every other day |
| Rats | 0.25–1 mg/kg | Subcutaneous | Daily |
| Humans | No established dose | Not approved | Not applicable |
No peer-reviewed human trial has defined a safe or effective MOTS-c injection dosage. Any number shared online for human use is an extrapolation, not a clinical guideline.
MOTS-c Injection Site and Administration Basics
In research settings, subcutaneous injections are often given into the abdominal wall or outer thigh. Choosing a clean mots-c injection site and rotating locations can reduce tissue irritation. Needle size, injection depth, and sterile handling all affect the reliability of the experiment.
Intraperitoneal injection, which delivers the peptide into the abdominal cavity, is common in rodents but not used in humans. For any injectable research peptide, follow institutional biosafety guidelines and dispose of sharps properly.
Safety, Side Effects, and Legal Status
MOTS-c is sold as a research chemical, not as a prescription drug. The FDA has not approved MOTS-c for any human condition. Reported side effects from animal studies are minimal, but human safety data are absent. Long-term effects of MOTS-c injection in humans are completely unknown.
Possible risks of any unregulated injection include infection, allergic reaction, dosing errors, and contamination. People considering MOTS-c for metabolic or performance goals should talk with a licensed healthcare professional first. Self-medicating with research peptides can cause harm.
How MOTS-c Compares to Other Injectable Peptides
MOTS-c is often discussed alongside other peptides, but the comparison is limited because most are studied for different purposes. For example, vyleesi injection is an FDA-approved bremelanotide product for hypoactive sexual desire disorder, not a metabolic peptide. Researchers comparing pt-141 nasal spray vs injection are evaluating delivery routes for a completely different compound.
| Peptide | Primary Research Area | Typical Route | FDA Status |
|---|---|---|---|
| MOTS-c | Metabolism, exercise mimicry | Subcutaneous (animal) | Not approved |
| PT-141 (bremelanotide) | Sexual desire | Subcutaneous, nasal | Approved as Vyleesi |
| BPC-157 | Tissue repair | Subcutaneous, oral | Not approved |
Bottom Line on MOTS-c Injection
MOTS-c injection remains an experimental technique with promising animal data and no confirmed human benefits. The peptide is not FDA-approved, and human dosing is unknown. Research is ongoing, but no human trials have been registered as of this writing. Anyone interested in MOTS-c should follow published research and consult a medical professional rather than relying on vendor claims.
Frequently Asked Questions
Is MOTS-c injection safe for humans?
No human safety data exist for MOTS-c injection, and the peptide is not FDA-approved. Animal studies show limited adverse effects, but that does not guarantee safety in people. Anyone considering it should consult a licensed healthcare provider first.
What is the typical MOTS-c injection dosage?
There is no established human dosage for MOTS-c. Animal studies commonly use 0.5 mg/kg in mice, but human equivalent doses are speculative and unsafe to assume. Do not use animal data to self-dose.
Where do you inject MOTS-c?
In research, subcutaneous injections are given into the abdomen or outer thigh, rotating sites to reduce irritation. Intraperitoneal injection is used in rodents but not in humans. Sterile technique and proper sharps disposal are essential.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.